ID   WM9 RL
AC   CVCL_E8FY
RX   PubMed=31877948;
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Left axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6806 ! WM9
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=31877948; DOI=10.3390/ijms21010113; PMCID=PMC6981576;
RA   Dratkiewicz, Ewelina
RA   Simiczyjew, Aleksandra
RA   Pietraszek-Gremplewicz, Katarzyna
RA   Wadzynska, Justyna
RA   Nowak, Dorota
RT   "Characterization of melanoma cell lines resistant to vemurafenib and
RT   evaluation of their responsiveness to EGFR- and MET-inhibitor
RT   treatment.";
RL   Int. J. Mol. Sci. 21:113.1-113.20(2019).
//